Aripiprazole and cariprazine in the augmentation of treatment-resistant depression: A review of efficacy, tolerability, and clinical applications
Pharmacotherapy in Psychiatry and Neurology · 2025 · 41 (2) · 97-110
DOI: 10.5114/fpn.2025.159506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy in Psychiatry and Neurology, 2025. Verfasst von Konrad Puchalski und 4 weiteren Autor:innen.
Themen: Depression
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Puchalski, K., Orzechowski, C., Radwańska, N., Janowiecka, P., & Skoczek, W. (2025). Aripiprazole and cariprazine in the augmentation of treatment-resistant depression: A review of efficacy, tolerability, and clinical applications. Pharmacotherapy in Psychiatry and Neurology, 41(2), 97-110. https://doi.org/10.5114/fpn.2025.159506
Vancouver
Puchalski K, Orzechowski C, Radwańska N, Janowiecka P, Skoczek W. Aripiprazole and cariprazine in the augmentation of treatment-resistant depression: A review of efficacy, tolerability, and clinical applications. Pharmacotherapy in Psychiatry and Neurology. 2025;41(2):97-110. doi:10.5114/fpn.2025.159506
BibTeX
@article{Puchalski2025,
author = {Puchalski, Konrad and Orzechowski, Cezary and Radwańska, Natalia and Janowiecka, Patrycja and Skoczek, Weronika},
title = {Aripiprazole and cariprazine in the augmentation of treatment-resistant depression: A review of efficacy, tolerability, and clinical applications},
journal = {Pharmacotherapy in Psychiatry and Neurology},
year = {2025},
volume = {41},
number = {2},
pages = {97--110},
doi = {10.5114/fpn.2025.159506}
}
EUVIMED